Board of Quipt Home Medical enters cooperation agreement with Kanen Wealth Management
Goodmans LLP represented the Board of Quipt Home Medical Corp. (or the “Board”) in connection with a notice from Philotimo Fund LP, an entity affiliated with Kanen Wealth Management LLC, announcing the intent to solicit proxies for four director candidates to Quipt’s board in opposition to the Board’s own candidates.
Philotimo Fund LP and President of KWM, David Kanen, filed the solicitation notice with the U.S. Securities and Exchange Commission on January 25, 2025.
On March 4, 2025, Quipt Home Medical Corp. (or the “Company”) announced that it has entered into a cooperation agreement with Kanen, under which Kanen agreed to withdraw its notice of its intent to solicit proxies in support of four director candidates at the Company’s Annual Meeting on March 17.
Pursuant to the agreement, the Board has granted Kanen certain Board access rights, if Kanen maintains aggregate beneficial ownership of at least 3.5 per cent of the Company's outstanding shares.
Quipt also agreed to establish a new committee of the Board to review and provide non-binding recommendations on Kanen’s previous suggestions related to corporate governance and other operational matters.
Kanen Wealth Management, LLC owns a 5.9 per cent stake in Quipt, placing it as the fourth-largest shareholder.
Quipt Home Medical provides in-home monitoring and disease management services, including end-to-end respiratory solutions, for patients in the United States healthcare market.Featured Work
-
Shareholder Activism
Board of Quipt Home Medical enters cooperation agreement with Kanen Wealth Management
Goodmans LLP represented the Board of Quipt Home Medical Corp. (or the “Board”) in connection with a notice from Philotimo Fund LP, an entity affiliated with Kanen Wealth Management LLC, announcing… -
Shareholder Activism
Roivant Sciences Ltd. announces resignation and replacement of Arbutus’ entire Board
Goodmans LLP acted for Roivant Sciences Ltd. in connection with its successful removal and replacement of all members of the Board of Directors of Arbutus Biopharma Corporation (or the “Board… -
Shareholder Activism
WonderFi Technologies Inc. announces board reshuffle
Goodmans LLP acted for the Board of Directors of WonderFi Technologies Inc. (or the “Board”) in connection with the restructuring of the WonderFi Board of Directors… -
Shareholder Activism
Browning West participates in the recruitment of CAE’s new CEO
Goodmans LLP acted for Browning West, LP in connection with its successful campaign to remove and replace certain members of the Board of Directors of CAE Inc. (including the Chair of the Board) and… -
Shareholder Activism
Browning West achieves landmark victory in Gildan Activewear proxy campaign
Goodmans LLP acted for Browning West, LP in the successful reconstitution of Gildan Activewear’s entire board, culminating in the reinstatement of CEO Glenn Chamandy… -
Shareholder Activism
FINSIGHT Group Inc. announces intent to vote against Q4 Inc’s proposed plan to be acquired by Sumeru Equity Partners
Goodmans LLP is acting for FINSIGHT Group Inc in connection with issuing a letter to the board of directors of Q4 Inc, announcing that it intends to vote AGAINST the Q4 Inc’s proposed plan of…